Loading organizations...
§ Venture Capital · Andover, MA, USA
Venture capital firm providing investments and asset management for biotech, focused on Alpha-1 Antitrypsin Deficiency.
A1ATD Investors is a venture capital and asset management firm. It specializes in strategic capital allocation for emerging companies in the financial sector. The firm identifies and funds innovative enterprises, participating in early-stage financing rounds like Series A, to provide financial support for growth-focused businesses.
Edward Krapels founded A1ATD Investors in 2017, based in Andover, Massachusetts. Krapels established the firm with understanding of specialized capital needs within biotech and healthcare. This insight led to a deliberate investment focus, consistent with its name, on advancements related to Alpha-1 Antitrypsin Deficiency.
The firm supports portfolio companies such as Apic Bio with early-stage funding. A1ATD Investors targets innovative life science and technology ventures seeking growth capital. Its mission advances specialized medical fields, facilitating novel solutions and treatments through strategic investment and diligent asset management, driving progress in unmet medical needs.
A1ATD Investors has 1 tracked investment across 1 company. The latest tracked deal is $42.0M Series A in Apic Bio in January 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 1, 2019 | Apic Bio | $42.0M Series A | Jason Dinges | ALS Investment Fund, The Alpha 1 Project |